Literature DB >> 9297995

A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group.

M Feeney1, A Ciegg, P Winwood, J Snook.   

Abstract

BACKGROUND: The cause of inflammatory bowel disease (IBD) remains to be established. Evidence has linked measles infection in early childhood with the subsequent risk of developing IBD, particularly Crohn's disease. A cohort study raised the possibility that immunisation with live attenuated measles vaccine, which induces active immunity to measles infection, might also predispose to the later development of IBD, provoking concerns about the safety of the vaccine.
METHOD: We report a case-control study of 140 patients with IBD (including 83 with Crohn's disease) born in or after 1968, and 280 controls matched for age, sex and general practitioner (GP) area, designed to assess the influence of measles vaccination on later development of IBD. Documentary evidence of childhood vaccination history was sought from GP and community health records.
FINDINGS: Crude measles vaccination rates were 56.4% in patients with IBD and 57.1% among controls. Matched odds ratios for measles vaccination were 1.08 (95% CI 0.62-1.88) in patients with Crohn's disease, 0.84 (0.44-1.58) in patients with ulcerative colitis, and 0.97 (0.64-1.47) in all patients with IBD.
INTERPRETATION: These findings provide no support for the hypothesis that measles vaccination in childhood predisposes to the later development of either IBD overall or Crohn's disease in particular.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9297995     DOI: 10.1016/s0140-6736(97)03192-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  25 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  MMR vaccine--worries are not justified.

Authors:  D A Elliman; H E Bedford
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

Review 4.  Detection of persistent measles virus infection in Crohn's disease: current status of experimental work.

Authors:  S Ghosh; E Armitage; D Wilson; P D Minor; M A Afzal
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

5.  Pertussis vaccination and wheezing illnesses in young children: prospective cohort study. The Longitudinal Study of Pregnancy and Childhood Team.

Authors:  J Henderson; K North; M Griffiths; I Harvey; J Golding
Journal:  BMJ       Date:  1999-05-01

Review 6.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 7.  Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature.

Authors:  Natasha-A Koloski; Laurel Bret; Graham Radford-Smith
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

8.  Measles virus and Crohn's disease: view of a medical virologist.

Authors:  V ter Meulen
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 9.  Pathogenesis of Crohn's disease: Bug or no bug.

Authors:  Marta Maia Bosca-Watts; Joan Tosca; Rosario Anton; Maria Mora; Miguel Minguez; Francisco Mora
Journal:  World J Gastrointest Pathophysiol       Date:  2015-02-15

Review 10.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.